Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from FDA

Why Verona Pharma Is Trading Higher By Around 84%, Here Are 85 Stocks Moving In Tuesday's Mid-Day Session

Gainers Verona Pharma plc (NASDAQ: VRNA) shares jumped 83.6% to $12.70 after the company announced ensifentrine met its primary endpoint and secondary endpoints in the Phase 3 ENHANCE-2 trial for COPD. The company also reported Q2 earnings results.

Nasdaq Tumbles 1.5%; BBQ Holdings Shares Spike Higher

Nasdaq Tumbles 1.5%; BBQ Holdings Shares Spike Higher

U.S. stocks traded lower midway through trading, with the Nasdaq dropping around 1.5% on Tuesday.

Why U.S. Stocks Are Trading Mixed; Labor Costs Increase Higher-Than-Expected In Q2

Why U.S. Stocks Are Trading Mixed; Labor Costs Increase Higher-Than-Expected In Q2

U.S. stocks traded mixed this morning, with the Nasdaq dropping around 90 points on Tuesday.

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Biotech Daily: Regulatory Setback For CorMedix, Mersana & GSK In Cancer Pact, BARDA Funding For Opioid Overdose Hopeful

Here's a roundup of top developments in the biotech space over the last 24 hours:

Why Is BIMI International Medical Higher By Around 70%: Here Are 38 Stocks Moving Premarket

Gainers BIMI International Medical Inc. (NASDAQ: BIMI) shares rose 69.6% to $1.04 in pre-market trading after Fnu Oudom reported a stake of 44% in the company in 13D.

Recap of Monday's Biotech Catalysts - End Of the Day Summary

Kodiak Sciences Inc. (NASDAQ:KOD) announced positive topline results its BEACON Phase 3 study of tarcocimab tedromer (KSI-301; tarcocimab) in patients with macular edema due to retinal vein occlusion. Kodiak shares traded in a range of $10.02 to $11.79 on a day volume of 4.05 million shares, closed regular trading session…

FDA Can't Stop Harassing Distillers Who Made Hand Sanitizer During the Pandemic

After 18 months of dealing with the FDA, some distillers are regretting making hand sanitizers at all.

inkl

Read news from The Economist, FT, and more,
with one subscription

Plan to axe 91,000 civil servants ‘only possible with cuts to services’

Plan to axe 91,000 civil servants ‘only possible with cuts to services’

Review casts doubt on Boris Johnson’s claim that frontline services would not be harmed

The Guardian - UK

LEXX: Put Your Drinks Up! Four Deals Signed in June

By John Vandermosten, CFA NASDAQ:LEXX READ THE FULL LEXX RESEARCH REPORT

Nature's secret drug stockpile

Nature's secret drug stockpile

Some scientists are looking for new drugs in nature rather than synthesizing them in the lab. Here's why

In fight against monkeypox, government isn’t learning from past experience

In fight against monkeypox, government isn’t learning from past experience

The Biden administration’s response has made key mistakes in handling the emerging threat. We hope this situation serves as a wake-up call to rethink and re-tool emergency response policies and practices.

Chicago Sun-Times

FDA considering "dose-sparing" approach to increase availability of Jynneos vaccine

FDA considering "dose-sparing" approach to increase availability of Jynneos vaccine

Health care providers could use one vial of the vaccine to administer up to five doses without an impact on safety or efficacy.

Biotech Daily: Thumbs Down For Acadia's Antipsychotic Drug, Akebia Fails COVID-19 Study, Kazia's Encouraging Data In Brain Metastases

Biotech Daily: Thumbs Down For Acadia's Antipsychotic Drug, Akebia Fails COVID-19 Study, Kazia's Encouraging Data In Brain Metastases

Here's a roundup of top developments in the biotech space over the last 24 hours:

Benzinga Before The Bell: Should Investors Worry About Tesla's China Sales, Gold Back In Focus, Nio Smartphone Could Soon Be A Reality Other Top Financial Stories Friday, August 5

Benzinga Before The Bell: Should Investors Worry About Tesla's China Sales, Gold Back In Focus, Nio Smartphone Could Soon Be A Reality Other Top Financial Stories Friday, August 5

CNBC International Airlines Prepare For Mayhem Of Summer Travel Season: Report

Get all your
news in one place.

100's of premium titles.
One news app.

The next public health emergency

Facing a groundswell of criticism for its sluggish response to monkeypox, the Biden administration declared a public health emergency on Thursday, potentially unlocking millions of dollars toward increasing vaccine availability in the U.S.

Recap Of Thursday's Biotech Catalysts - End Of the Day Summary

The European Commission (EC) has approved AstraZeneca (NASDAQ: AZN) and Merck’s (NYSE: MRK) LYNPARZA as monotherapy or in combination with endocrine therapy for the adjuvant treatment of adult patients with germline B

NYC and San Francisco Prioritize 'First Doses First' for Monkeypox Vaccine. Why Won't the CDC Do the Same?

The CDC and FDA, when confronted with scarce vaccine supply, refuse to learn from their COVID-19 mistakes.

Administration declares monkeypox a public health emergency - Roll Call

The administration declares monkeypox a public health emergency and says it will make it easier to get vaccines to patients.

Get all your
news in one place.

100's of premium titles.
One news app.

Monkeypox Is Giving Public Health Agencies a Chance To Prove They've Learned Nothing From COVID

Plus: Schools surveilling students online, Tim Wu leaving the White House, and more...

Biotech Daily: Amgen, Gilead Go Shopping, Nod For AstraZeneca's Lynparza In Early Stage Breast Cancer, Decision Day For Alzheimer's Associated Hallucinations Candidate

Here's a roundup of top developments in the biotech space over the last 24 hours:

The Conversation

The US government’s call for deep nicotine reduction in cigarettes could save millions of lives – an expert who studies tobacco addiction explains

The cigarette is the only legal consumer product that – when used as intended – causes the premature death of half of long-term users.

Alternate monkeypox treatment caught in regulatory delays

Alternate monkeypox treatment caught in regulatory delays

Recap Of Wednesday's Biotech Catalysts - End Of the Day Summary

The U.S. Food and Drug Administration (FDA) has accepted for review MediWound’s (NASDAQ:MDWD) recently re-submitted Biologics License Application (BLA) for its lead asset NexoBrid for eschar removal (debridement) in adults with deep partial-thickness and/or full-thickness thermal burns. MediWound shares traded in a range of $1.6 to $1.76 on a day…

The Independent UK

How common is Paxlovid rebound as Biden tests positive again for Covid?

Paxlovid good at stopping hospitalisation for high-risk groups, despite occasional rebound

Biotech Daily: Merck's Two Combo Cancer Trials Miss Main Goal, Approval For Sinovac's COVID-19 Shot For Youngest Kids, Alnylam Aces Protein Disorder Trial

Here's a roundup of top developments in the biotech space over the last 24 hours:

1 … 177 178 179 180

People

180,205 stories

John Vandermosten

[ Richard M. ] Burr

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Organisations

inkl

Read news from The Economist, FT, and more,
with one subscription

Topics

Prostate Cancer

Places

360,495 stories

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play